Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera
2024 · New England Journal of Medicine · 41 citations
https://doi.org/10.1056/nejmoa2308809
A
Andrew Kuykendall
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
536
Papers
2.8K
Citations
25
h-index
66
i10-index
Andrew Kuykendall is an academic researcher from Moffitt Cancer Center. The author has contributed to research in topics: Myeloproliferative Neoplasms: Diagnosis and Treatment & Acute Myeloid Leukemia Research & Chronic Myeloid Leukemia Treatments. The author has an h-index of 25, co-authored 456 publications.
ORCID: 0000-0002-9040-7415Papers by this author
worksJAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation
2022 · Blood Cancer Journal · 29 citations
https://doi.org/10.1038/s41408-022-00609-5
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial
2025 · Nature Medicine · 23 citations
https://doi.org/10.1038/s41591-025-03572-3
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients
2022 · Leukemia · 18 citations
https://doi.org/10.1038/s41375-022-01673-3
Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML
2024 · Annals of Hematology · 12 citations
https://doi.org/10.1007/s00277-024-05760-6
Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies
2025 · Leukemia · 9 citations
https://doi.org/10.1038/s41375-025-02515-8
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat